English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 21 December 2020, 19:00 HKT/SGT
Share:
China Medical System (00867.HK) MSCI-ESG Rating Upgraded to AA, Reaching Global Level

HONG KONG, Dec 21, 2020 - (ACN Newswire) - Morgan Stanley Capital International (MSCI) issued a report on December 17 upgrading the ESG (Environmental, Social and Governance) Rating for China Medical System Holdings Limited ("China Medical System"), a well-established, innovation-driven specialty pharma with a focus on sales & marketing in China. China Medical System's ESG Rating has been upgraded from "BBB" to "AA", surpassing 88% of companies in the global pharmaceutical industry, symbolizing that the Company has attained a level among its global peers in ESG management.

MSCI recognized China Medical System's outstanding performance in Corporate Governance, Corporate Behavior, Product Safety and Quality, Human Capital Development, and Access to Health Care, noting that the Company "Leads peers in business ethics and talent management practices". MSCI also gave a positive assessment of the Company's Corporate Behavior, "China Medical System has evidence of detailed policies on business ethics and corruption".

There are seven levels of the MSCI-ESG Rating, from the highest to the lowest are AAA, AA, A, BBB, BB, B, and CCC. Among them, companies with AA or AAA ratings are considered to be industry leaders in managing the most significant ESG risks and opportunities. This year, China Medical System's MSCI-ESG Rating has been upgraded by three levels, from BB to AA.

According to the Company, "Receiving the AA ESG Rating from MSCI reflected China Medical System's long-term focus and resource investment on ESG management and information disclosure, and affirmed the Company's compliance focus and solid business practices. In recent years, with leadership from the Board of Directors, the Company's ESG-related policies have increasingly improved, ESG practices are more standardized, and ESG management is constantly refined.

"In the future, through self-challenge and transcendence, China Medical System will continuously pursue higher corporate governance goals. The Company will continuously regard innovation as its driving force, to fulfill the unmet medical needs, and contribute to the integrated development of society, the environment, and civilization."


Topic: Rating Report
Source:

Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Scout and eFanGage Enter Agreement to Deliver In-Venue Sports Engagement Platform to the U.S.  
Sept 22, 2021 22:00 HKT/SGT
Westar launches first permissionless public chain, Starcoin  
Sept 22, 2021 21:00 HKT/SGT
TrustToken Acquires EthWorks; Doubling Team Size for TrueFi Scale-Up  
Sept 22, 2021 20:46 HKT/SGT
Mitsubishi Heavy Industries Engineering Partners in New Concession of Dubai Metro and Dubai Tram in Joint Venture with Keolis and Mitsubishi Corp.  
Sept 22, 2021 18:11 HKT/SGT
TOYOTA GAZOO Racing Announces Four-Car Team and All-New Toyota GR DKR Hilux T1+ for Dakar 2022  
Sept 22, 2021 18:00 HKT/SGT
Mandalika Circuit to have Multiplier Effect on Lombok Tourism  
Sept 22, 2021 16:00 HKT/SGT
SDK and SDMC Nominate H. Takahashi as New President and CEO  
Sept 22, 2021 14:00 HKT/SGT
NEC Iris Recognition Technology Ranks first in NIST Accuracy Testing  
Sept 22, 2021 11:02 HKT/SGT
Nano Labs Completed Another Round of Equity Financing Raising Tens of Millions of US  
Sept 22, 2021 11:00 HKT/SGT
Cielo Maintains No. 1 Global Ranking on 2021 HRO Today's RPO Baker's Dozen  
Sept 22, 2021 09:00 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575